Growth hormone treatment strategies in assisted reproduction for the poor responder patients

  • Liailia Kh. Dzhemlikhanova St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation ; Department of Assisted Reproduction Technologies, FSBI D. O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 3, Mendeleevskaya liniya, St. Petersburg, 199034, Russian Federation
  • Ksenia V. Ob’edkova St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation ; Department of Assisted Reproduction Technologies, FSBI D. O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 3, Mendeleevskaya liniya, St. Petersburg, 199034, Russian Federation
  • Dariko A. Niauri St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation ; Department of Assisted Reproduction Technologies, FSBI D. O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 3, Mendeleevskaya liniya, St. Petersburg, 199034, Russian Federation
  • Igor Yu. Kogan St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation ; Department of Assisted Reproduction Technologies, FSBI D. O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 3, Mendeleevskaya liniya, St. Petersburg, 199034, Russian Federation
  • Maria A. Mazilina St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation ; Department of Assisted Reproduction Technologies, FSBI D. O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 3, Mendeleevskaya liniya, St. Petersburg, 199034, Russian Federation
  • Inna O. Krikheli Department of Assisted Reproduction Technologies, FSBI D. O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 3, Mendeleevskaya liniya, St. Petersburg, 199034, Russian Federation
  • Irina D. Mekina Department of Assisted Reproduction Technologies, FSBI D. O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 3, Mendeleevskaya liniya, St. Petersburg, 199034, Russian Federation
  • Elena A. Lesik Department of Assisted Reproduction Technologies, FSBI D. O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 3, Mendeleevskaya liniya, St. Petersburg, 199034, Russian Federation
  • Evgenia M. Komarova Department of Assisted Reproduction Technologies, FSBI D. O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 3, Mendeleevskaya liniya, St. Petersburg, 199034, Russian Federation

Аннотация

The goal of the study was to estimate the efficacy of growth hormone (GH) co-treatment to the antagonist protocol in IVF/ ICSI cycles in poor responders. A prospective observational study involved 75 patients. All patients underwent standard antagonist protocol with or without GH co-treatment. GH additional was given a daily subcutaneous injection of 1.33 mg (equivalent to 4 IU) of GH from day 1 of ovarian stimulation until the day of human chorionic gonadotropin (hCG). Concentrations of GH, insulin-like growth factor I (IGF-I) and IGF binding protein-3 (IGFBP-3) in serum and follicular fluid were analyzed. The GH co-treatment significantly lowered effective dose of gonadotropins, duration of stimulation, IGFBP-3 level in serum and follicular fluid day of oocytes retrieval. The number of oocytes recovered, metaphase II stage (MII) oocytes, 2 pronucleus (2 pn) zygote, good-quality transferred embryos were significantly higher in the GH+ group. Only patients GH+ group became pregnant. Positive correlation was found between IGF-I level in follicular fluid, dynamics of IGFBP-3 level changes during stimulation protocol and number of good-quality transferred embryos in the GH+ group. GH administration in IVF/ICSI cycles for poor responders raises ovarian sensitivity to the gonadotropin exogenous influence, this way, increasing number of high-quality embryos and the probability of pregnancy.

Скачивания

Данные скачивания пока недоступны.
 

Литература


References

Ferraretti A. P., La Marca A., Fauser B. C. J. M., Tarlatzis B., Nargund G., Gianaroli L. ESHRE consensus on the definition of “poor response” to ovarian stimulation for in vitrofertilization: the Bologna criteria.Hum. Reprod., 2011, vol. 26, pp. 1616–1624.

Kyrou D., Kolibianakis E. M., Venetis C. A., Papanikolaou E. G., Bontis J., Tarlatzis B. C. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil. Steril., 2009, vol. 91, pp. 749–766.

Owen E. J., West C., Mason B. A., Jacobs H. S. Cotreatment with growth hormone of sub-optimal responders in IVF-ET. Hum. Reprod., 1991, vol. 6, pp. 524–528.

Homburg R., Eshel A., Abdalla H. I., Jacobs H. S. Growth hormone facilitates ovulation induction by gonadotrophins. Clinical Endocrinology,1988, vol. 29, pp. 113–117.

Schwarzler P., Untergasser G., Hermann M. et al. Selective growth hormone/placental lactogen gene transcription and hormone production in pre- and postmenopausal human ovaries. The Journal of Clinical Endocrinology and Metabolism, 1997, vol. 82, pp. 3337–3341.

Abir R. Garor R., Felz C., Nitke S., Krissi H., Fisch B. Growth hormone and its receptor in human ovaries from fetuses and adults. Fertil. Steril., 2008, vol. 90, pp. 1333– 1339.

Kucuk T., Kozinoglu H., Kaba A. Growth hormone cotreatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial. Journal of Assisted Reproduction and Genetics, 2008, vol. 25, pp. 123-127.

De Ziegler D., Streuli I., Meldrum D. R., Chapron C. The value of growth hormone supplements in ART for poor ovarian responders. Fertil. Steril., 2011, vol. 96, pp. 1069–1076.

Kolibianakis E. M., Venetis C. A., Diedrich K., Tarlatzis B. C., Griesinger G. Addition of growth hormone to gonadotrophins in ovarian stimulationof poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum. Reprod., 2009, vol. 15, pp. 613–622.

Hazout A., Junca A. M., Menezo Y., de Mouzon J., Cohen-Bacrie P. Effect of growth hormone on oocyte competence in patients with multiple IVF failures. Reproductive BioMedicine Online, 2009, vol. 18, pp. 664–670.

Duffy J. M. N., Ahmad G., Mohiyiddeen L., Nardo L. G., Watson A. Growth hormone for in vitro fertilization (Review). Cochrane Database Syst Rev., 2010, no. 1, p. CD000099.

Rajesh H., Yong Y. Y., Zhu M., Chia D., Yu S. L. Growth hormone deficiency and supplementation at in-vitro fertilization. Singapore Medical Journal, 2009, vol. 48, pp. 514–518.

Hsu C., Hammond J. Concomitant effects of growth hormone on secretion of insulin-like growth factor I and progesterone by cultured porcine granulosa cells in vitro. Endocrinology, 1988, vol. 120, pp. 198–207.

Barecca A., Artini P. G., Del Monte P., Ponzani P., Pasquini P., Cariola G. In vivo and in vitro effect of growth hormone on estradiol secretion by granulosa cells. J. Clin. Endocrinol. Metab., 1993, vol. 77,pp. 61–67.

Tesarik J., Hazout A., Mendoza C. Improvement of delivery and live birth rates after ICSI in womenaged >40 years by ovarian co-stimulation with growth hormone. Hum. Reprod., 2005, vol. 20, pp. 2536–2541.

Mendoza C., Ruiz-Requena E., Ortegaetal E. Follicular fluid markers of oocyte developmental potential. Hum. Reprod., 2002, vol. 17, pp. 1017–1022.

Kokshoorn N. E., Biermasz N. R., Roelfsema F., Smit J. W. A., Pereira A. M., Romijn J. A. GH replacement therapy in elderly GH-deficient patients: a systematic review. European Journal of Endocrinology, 2011, vol. 164, pp. 657–665.
Опубликован
2019-11-14
Как цитировать
Dzhemlikhanova, L. K., Ob’edkova, K. V., Niauri, D. A., Kogan, I. Y., Mazilina, M. A., Krikheli, I. O., Mekina, I. D., Lesik, E. A., & Komarova, E. M. (2019). Growth hormone treatment strategies in assisted reproduction for the poor responder patients. Вестник Санкт-Петербургского университета. Медицина, 14(2), 132–140. https://doi.org/10.21638/10.21638/spbu11.2019.205
Раздел
Акушерство и гинекология